Using celecoxib with chemotherapy for metastatic colorectal cancer
Evaluation of Anticancer Effect of Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer
This study is testing if adding celecoxib to standard chemotherapy can help people with metastatic colorectal cancer get better results from their treatment.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Tanta, Elgharbia) |
| Trial ID | NCT03645187 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of celecoxib as an additional treatment alongside chemotherapy in patients suffering from metastatic colorectal cancer. The primary goal is to assess whether celecoxib can enhance the anticancer effects of standard chemotherapy regimens, specifically FOLFERI. Participants will receive both the chemotherapy and celecoxib to determine any improvements in treatment outcomes. The study is designed to provide insights into the potential benefits of combining these therapies for better patient management.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with advanced colorectal cancer who are eligible for chemotherapy.
Not a fit: Patients with cerebral metastases, other malignancies, H pylori infection, or a history of thromboembolism may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve treatment outcomes for patients with metastatic colorectal cancer.
How similar studies have performed: Other studies have explored the use of celecoxib in cancer treatment, showing promising results, but this specific combination is being evaluated for the first time.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * advanced colorectal cancer Exclusion Criteria: * cerebral metastases * other malignancy * H pylori infection * thromboembolism
Where this trial is running
Tanta, Elgharbia
- Amira Roushdy — Tanta, Elgharbia, Egypt (Recruiting)
Study contacts
- Principal investigator: Tarek M Mostafa, Prof — Clinical pharmacy Department- Tanta University
- Study coordinator: Sherief Abd-Elsalam, MD
- Email: sheriefabdelsalam@yahoo.com
- Phone: 00201147773440
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.